Method of screening of therapeutic agents for K-Ras mutant driven cancers
US9400281B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 31, 2013 |
| Grant date | Jul 26, 2016 |
| Priority date | — |
| Expiry date | Dec 31, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.